Randomized trial reveals lower all-cause mortality with high-dose hemodiafiltration versus high-flux hemodialysis in kidney failure, indicating survival benefits of advanced blood filtration.
In patients with kidney failure resulting in kidney-replacement therapy, the use of high-dose hemodiafiltration resulted in a lower risk of death from any cause than conventional high-flux hemodialysis. (Funded by the European Commission Research and Innovation; CONVINCE Dutch Trial Register number, NTR7138.).
No takes yet. Share an insight, caveat, or question.
Blankestijn et al. (2023) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: